ArticleWorld journal of gastrointestinal oncology2025
Significance of serum APE1-AAbs, PTX-3, and miR-486-3p in patients with colorectal cancer undergoing radical surgery.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a common malignant tumor of the digestive tract worldwide, characterized by high incidence and mortality rates.
aimTo investigate the expression of serum apurinic/apyrimidinic endonuclease 1 autoantibodies (APE1-AAbs), peripheral pentraxin-3 (PTX-3), and miR-486-3p in patients with CRC undergoing radical surgery and their relationship with postoperative recurrence and metastasis.
methodsA retrospective analysis was conducted on the clinical data of 154 CRC patients who underwent laparoscopic radical surgery in our hospital from January 2022 to January 2024. Patients were followed for one year postoperatively and divided into an occurrence group (
resultsThe occurrence group had significantly higher proportions of patients with an age ≥ 60 years, lymph node metastasis, stage III disease, poor differentiation, tumor diameter > 5 cm, and higher platelet count, carcinoembryonic antigen, and carbohydrate antigen 19-9 levels than the non-occurrence group (
conclusionSerum APE1-AAbs, PTX-3, and miR-486-3p levels are higher in CRC patients with postoperative recurrence and metastasis. These three markers are risk factors for postoperative recurrence and metastasis in CRC and can be used as predictive biomarkers. The combined detection of these markers has higher predictive value compared to individual tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.